Abstract: Quinoxalinedione derivatives of formula (I) ##STR1## are described, and their use in pharmaceutical agents.

Abstract: Compounds of formula I ##STR1## are useful for treating TNF-mediated diseases.

Abstract: This invention relates to (R)-(-)-methylphenyloxazolidinone derivatives, a process for their production and their use as pharmaceutical agents.

Abstract: Described are racemic and enantiomerically pure chiral phenyldihydrofuranones, their preparation and their use in drugs (selective inhibition of the cAMP-specific phosphodiesterase IV).

Abstract: In a method of making deformation Lest samples of metallic mechanically rigid, single crystals as they are required as sample rods for tension-, compression-, or bending tests in the precision testing of materials, the samples are first generated by known methods as cylindrical raw single crystals having varying diameters and rough surfaces. The raw single crystals are then shaped by wire erosion to provide testing samples of a desired shape and surface quality.

Abstract: An apparatus for single-axis examinations of micro samples in a tensile testing machine having opposite pull rods between which the apparatus is mounted for the application of tensile forces to a micro-sample includes a load frame for the connection to the pull rods which load frame comprises two parallel spring frame structures in the form of serially arranged cantilever beams defining multiple S structures interconnecting a bottom and a top frame part, sample mounting means mounted on one of the parts, a force measuring element mounted on the other frame part and including hydraulic sample mounting means and flexible means which bend depending on the pulling force applied thereto and which have tension measuring means to measure the bending extent and means for sensing the movement of the second mounting means relative to the one frame part.

Abstract: Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a triazine or benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1are useful pharmaceutical agents.

Abstract: The use of NMDA receptor antagonists or their physiologically compatible salts for preventing the development of tolerance during the long-term treatment with benzodiazepine-receptor-binding active ingredients as well as the combination of new pharmaceutical agents with benzodiazepine-receptor-binding active ingredients is described.

Abstract: A medical insufflation device having a control device with feedback sensors for regulating the flow of a gas into an inflatable body cavity. The device includes a conduit for channeling gas from a gas supply into an insufflation instrument, sensors for measuring gas pressure and gas flow in the conduit, and a control device responsive to the sensors for automatically regulating the pressure and flow of the gas into the body cavity from the conduit. The control device has an automatic processing unit for receiving the measured gas pressure and flow values from the sensors and for using those values to control an actuator in the conduit and which is operatively adjustable for regulating the flow of gas into the body cavity.

Abstract: Compounds of formula I are described ##STR1## in which R.sup.3 represents a C.sub.6-12 -aryl or hetaryl radical, optionally substituted singly or multiply with C.sub.1-4 -alkyl, C.sub.3-7 -cycloalkyl, halogen, C.sub.1-4 -alkoxy-C.sub.1-2 -alkyl, phenyl or amino, the process for their production and their use in pharmaceutical agents.

Abstract: .beta.-carbolines of formula I are described ##STR1## in which R.sup.A is a C.sub.6-12 aryl hetaryl as defined herein, that can be substituted singly to multiply with halogen, C.sub.1-4 -alkoxy, C.sub.1-4 -alkyl or amino,X is --(CH.sub.2).sub.n -- or --C.tbd.C--,for use as pharmaceutical agents.

Abstract: In a method and device for controlling an internal combustion engine, the fuel quantity injected into the combustion chambers of the internal combustion engine and/or the start of pump delivery are determined by means of a pressure sensor. In so doing, a duration-of-pump-delivery signal, which represents a measure for the injected fuel quantity, is predefined on the basis of a start-of-pump-delivery signal and an end-of-pump-delivery signal. The start-of-pump-delivery signal and/or the end-of-pump-delivery signal are recognized as being plausible when the duration-of-pump-delivery signal is greater than a first threshold value.

Abstract: The invention relates to a transmission system comprising a transmitter (100) which includes a coder for coding an information signal (11) into a digital signal (11, 12) constituted by the information signal (11) and a redundancy signal (12), the redundancy signal (12) being generated by way of a cyclic code from the information signal (11 ), and comprising a receiver (101) which includes a decoder with a storage unit (2) for storing the information signal (11) and with an error correction means which has an optionally feedback shift register (3) for processing the digital signal (11, 12). The transmission system is to make both the correction of burst errors as well as the correction of random errors possible in a single error correction means. There is proposed that the error correction means of the decoder comprises a burst error detection means (4) for producing a first error information signal (B) from predeterminable storage contents (S.sub.0 . . . S.sub.

Abstract: .beta.-carboline-3-hydroxyalkylcarboxylic acid ester derivatives of formula I ##STR1## in which R.sup.A, n, R.sup.4 and R.sup.3, have the meaning indicated in the claims, as well as their production and their use in pharmaceutical agents are described.

Abstract: Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 are useful pharmaceutical agents.

Abstract: 4-Isoxazolyl-imidazole derivatives of formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings indicated, as well as their production and use in pharmaceutical agents, are described.

Abstract: .beta.-Carbolines of general Formula I ##STR1## wherein Y represents the residue ##STR2## and R.sup.a and R.sup.b, being identical or different, mean respectively hydrogen, C.sub.1-6 -alkoxy, phenyl, C.sub.3-7 -cyclo-alkyl, optionally substituted C.sub.1-6 -alkyl or C.sub.1-6 -alkoxycarbonyl, and R.sup.c and R.sup.d, being identical or different, mean respectively hydrogen or C.sub.1-6 -alkyl or jointly a linkage, andR.sup.4 is hydrogen, C.sub.1-6 -alkyl or C.sub.1-6 -alkoxy-C.sub.1-6 -alkyl andR.sup.5 is hydrogen, halogen, OR.sup.6, NR.sup.7 R.sup.8 or CH R.sup.9 R.sup.10 wherein R.sup.6 means C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl or an optionally substituted aralkyl, aryl or hetaryl residue, R.sup.7 and R.sup.8, being identical or different, represent hydrogen, C.sub.1-6 -alkyl, C.sub.3-6 -alkenyl, or jointly with the nitrogen atom a saturated heterocyclic five- or six-membered ring which optionally contains a further hetero atom, R.sup.9 means hydrogen or C.sub.1-6 -alkyl, R.sup.10 means hydrogen, C.sub.

Abstract: For the establishment of vertual connections passing through switching matrices of a multi-stage switching system, it is provided that upon the arrival of a call packet requesting the establishment of a virtual connection, a central control device identifies all the switching matrices involved in the connection to be established and determines setup information that must be assigned to each of them in order to establish the connection. This setup information is fed to the individual switching matrices from the central control device in a setup packet along the path of the virtual connection to be established.

Abstract: (2-Haloergolinyl)-N',N'-diethylurea derivatives of Formula I ##STR1## and the salts thereof, wherein R is hydrogen, alkyl of up to 6 carbon atoms, or alkenyl of up to 3 carbon atoms,X is halogen, ##STR2## is a CC single or CC double bond, and the urea residue in the 8-position can be in the .alpha.- or .beta.-configuration, have neuropsychotropic properties.As a result, they are excellently suitable for treatment of psychotic disturbances and emesis.

Abstract: Ergolinyl compounds which are nitrogen-substituted in the 8-position and have Formula (I) ##STR1## and physiologically compatible salts thereof, wherein (a) R.sup.1 is hydrogen, the 8-substituent can be in the .alpha.- or .beta.-position and ##STR2## represents a single or a double bond, R.sup.2 is hydrogen, C.sub.1-4 -alkyl or C.sub.1-7 -acyl,R.sup.3 is hydrogen, chlorine or bromine, andR.sup.4 is C.sub.1-6 -alkyl, C.sub.3-6 -cycloalkyl-C.sub.1-3 -alkyl, C.sub.3-6 -alkenyl, or C.sub.3-6 -alkynyl; or(b) R.sup.1 is ##STR3## and the 8-substituent can be in the .alpha.- or .beta.-position, ##STR4## represents a single or double bond, R.sup.2, R.sup.3 are as defined above,R.sup.4, is C.sub.1.varies.6 -alkyl, C.sub.3-6 -cycloalkyl-C.sub.1-3 -alkyl, C.sub.3-6 -alkenyl, or C.sub.3-6 -alkynyl; andR.sup.5 is hydrogen, C.sub.-10 -alkyl, C.sub.3-10 -alkenyl, or C.sub.3-10 -alkynyl, andR.sup.6 is C.sub.1-10 -alkyl, C.sub.3-10 -alkenyl, C.sub.3-10 -alkynyl, or aryl, orR.sup.5 and R.sup.